These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1358 related items for PubMed ID: 15030341

  • 1. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.
    Reitamo S, Harper J, Bos JD, Cambazard F, Bruijnzeel-Koomen C, Valk P, Smith C, Moss C, Dobozy A, Palatsi R, European Tacrolimus Ointment Group.
    Br J Dermatol; 2004 Mar; 150(3):554-62. PubMed ID: 15030341
    [Abstract] [Full Text] [Related]

  • 2. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis.
    Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Fölster-Holst R, Vena G, Bos JD, Fabbri P, Groenhoej Larsen C, European Tacrolimus Ointment Study Group.
    Br J Dermatol; 2005 Jun; 152(6):1282-9. PubMed ID: 15948994
    [Abstract] [Full Text] [Related]

  • 3. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial.
    Doss N, Reitamo S, Dubertret L, Fekete GL, Kamoun MR, Lahfa M, Ortonne JP.
    Br J Dermatol; 2009 Aug; 161(2):427-34. PubMed ID: 19416227
    [Abstract] [Full Text] [Related]

  • 4. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study.
    Schachner LA, Lamerson C, Sheehan MP, Boguniewicz M, Mosser J, Raimer S, Shull T, Jaracz E, US Tacrolimus Ointment Study Group.
    Pediatrics; 2005 Sep; 116(3):e334-42. PubMed ID: 16140675
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of tacrolimus ointment in pediatric Patients with moderate to severe atopic dermatitis.
    Singalavanija S, Noppakun N, Limpongsanuruk W, Wisuthsarewong W, Aunhachoke K, Chunharas A, Wananukul S, Akaraphanth R.
    J Med Assoc Thai; 2006 Nov; 89(11):1915-22. PubMed ID: 17205874
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis.
    Bieber T, Vick K, Fölster-Holst R, Belloni-Fortina A, Städtler G, Worm M, Arcangeli F.
    Allergy; 2007 Feb; 62(2):184-9. PubMed ID: 17298428
    [Abstract] [Full Text] [Related]

  • 7. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use.
    Paller AS, Eichenfield LF, Kirsner RS, Shull T, Jaracz E, Simpson EL, US Tacrolimus Ointment Study Group.
    Pediatrics; 2008 Dec; 122(6):e1210-8. PubMed ID: 19015204
    [Abstract] [Full Text] [Related]

  • 8. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
    Ling M, Gottlieb A, Pariser D, Caro I, Stewart D, Scott G, Abrams K.
    J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
    [Abstract] [Full Text] [Related]

  • 9. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study.
    Pacor ML, Di Lorenzo G, Martinelli N, Mansueto P, Rini GB, Corrocher R.
    Clin Exp Allergy; 2004 Apr; 34(4):639-45. PubMed ID: 15080819
    [Abstract] [Full Text] [Related]

  • 10. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment.
    Wollenberg A, Reitamo S, Girolomoni G, Lahfa M, Ruzicka T, Healy E, Giannetti A, Bieber T, Vyas J, Deleuran M, European Tacrolimus Ointment Study Group.
    Allergy; 2008 Jul; 63(7):742-50. PubMed ID: 18592619
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment.
    Doss N, Kamoun MR, Dubertret L, Cambazard F, Remitz A, Lahfa M, de Prost Y.
    Pediatr Allergy Immunol; 2010 Mar; 21(2 Pt 1):321-9. PubMed ID: 19563466
    [Abstract] [Full Text] [Related]

  • 12. Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic CONTROL study.
    Poole CD, Chambers C, Sidhu MK, Currie CJ.
    Br J Dermatol; 2009 Dec; 161(6):1335-40. PubMed ID: 19754867
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis.
    Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, Cambazard F, Rustin M, Taïeb A, Gratton D, Sauder D, Sharpe G, Smith C, Jünger M, de Prost Y, European /Canadian Tacrolimus Ointment Study Group.
    J Allergy Clin Immunol; 2002 Mar; 109(3):539-46. PubMed ID: 11898004
    [Abstract] [Full Text] [Related]

  • 14. Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: an open-label pilot study.
    Kubota Y, Yoneda K, Nakai K, Katsuura J, Moriue T, Matsuoka Y, Miyamoto I, Ohya Y.
    J Am Acad Dermatol; 2009 Feb; 60(2):212-7. PubMed ID: 19027990
    [Abstract] [Full Text] [Related]

  • 15. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study.
    Thaçi D, Reitamo S, Gonzalez Ensenat MA, Moss C, Boccaletti V, Cainelli T, van der Valk P, Buckova H, Sebastian M, Schuttelaar ML, Ruzicka T, European Tacrolimus Ointment Study Group.
    Br J Dermatol; 2008 Dec; 159(6):1348-56. PubMed ID: 18782319
    [Abstract] [Full Text] [Related]

  • 16. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double-blind, comparative trial.
    Mandelin J, Remitz A, Virtanen H, Reitamo S.
    Acta Derm Venereol; 2010 Mar; 90(2):170-4. PubMed ID: 20169301
    [Abstract] [Full Text] [Related]

  • 17. Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies.
    Reitamo S, Allsopp R.
    J Dermatolog Treat; 2010 Jan; 21(1):34-44. PubMed ID: 20055695
    [Abstract] [Full Text] [Related]

  • 18. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients.
    Reitamo S, Rustin M, Harper J, Kalimo K, Rubins A, Cambazard F, Brenninkmeijer EE, Smith C, Berth-Jones J, Ruzicka T, Sharpe G, Taieb A, 0.1% Tacrolimus Ointment Long-term Follow-up Study Group.
    Br J Dermatol; 2008 Sep; 159(4):942-51. PubMed ID: 18637898
    [Abstract] [Full Text] [Related]

  • 19. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial.
    Gong JQ, Lin L, Lin T, Hao F, Zeng FQ, Bi ZG, Yi D, Zhao B.
    Br J Dermatol; 2006 Oct; 155(4):680-7. PubMed ID: 16965415
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis.
    Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, Schoepf E, Lahfa M, Diepgen TL, Judodihardjo H, Wollenberg A, Berth-Jones J, Bieber T, European Tacrolimus Ointment Study Group.
    J Allergy Clin Immunol; 2002 Mar; 109(3):547-55. PubMed ID: 11898005
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.